Literature DB >> 25449778

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Dieter J E Peeters1, Anja Brouwer2, Gert G Van den Eynden2, Annemie Rutten3, Wendy Onstenk4, Anieta M Sieuwerts4, Steven J Van Laere5, Philippe Huget3, Patrick Pauwels6, Marc Peeters7, Peter B Vermeulen2, Luc Y Dirix2.   

Abstract

We have shown that in up to half of the patients with metastatic breast cancer (MBC), higher numbers of circulating tumour cells (CTCs) are present in the central venous blood (CVB) compared to the peripheral venous blood (PVB), suggesting that the lungs might retain a substantial number of CTCs. Here we report the presence of tumour cell emboli (TCE) in the microvasculature of the lungs in three out of eight patients with MBC and one patient with metastatic cervical carcinoma who had markedly elevated numbers of CTCs in the blood. All these patients suffered from symptomatic dyspnoea not easily attributable to other causes. No TCE were observed in five patients with MBC and elevated CTC counts and three patients with MBC who had low CTC counts (<5/7.5 ml). To investigate whether CTCs derived from CVB or PVB exhibit different transcriptional characteristics that might explain selective CTC retention, paired CTC samples from CVB and PVB of 12 patients with advanced breast cancer were subjected to gene expression analysis of 105 genes. No significant differences in CTC gene expression were observed. Together, these data suggest that potentially clinically relevant CTC retention in the microvasculature of the lung can occur in a subset of patients with advanced metastatic breast and cervical cancer, which seems to be transcriptionally non-selectively.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Circulating tumour cells; Dyspnoea; Gene expression profiling; Metastasis biology; Pulmonary tumour cell emboli

Mesh:

Substances:

Year:  2014        PMID: 25449778     DOI: 10.1016/j.canlet.2014.10.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.

Authors:  Vasudha Murlidhar; Rishindra M Reddy; Shamileh Fouladdel; Lili Zhao; Martin K Ishikawa; Svetlana Grabauskiene; Zhuo Zhang; Jules Lin; Andrew C Chang; Philip Carrott; William R Lynch; Mark B Orringer; Chandan Kumar-Sinha; Nallasivam Palanisamy; David G Beer; Max S Wicha; Nithya Ramnath; Ebrahim Azizi; Sunitha Nagrath
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

Review 2.  Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.

Authors:  Yupeng Hong; Qi Zhang
Journal:  Tumour Biol       Date:  2016-01-13

3.  Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells.

Authors:  Heming Li; Qing H Meng; Hyangsoon Noh; Izhar Singh Batth; Neeta Somaiah; Keila E Torres; Xueqing Xia; Ruoyu Wang; Shulin Li
Journal:  Cancer Lett       Date:  2017-06-23       Impact factor: 8.679

Review 4.  Circulating tumor cell clusters: What we know and what we expect (Review).

Authors:  Yupeng Hong; Francia Fang; Qi Zhang
Journal:  Int J Oncol       Date:  2016-10-24       Impact factor: 5.650

5.  Prognostic value of circulating tumor cells in esophageal cancer.

Authors:  Hai-Tao Xu; Jing Miao; Jian-Wei Liu; Lian-Guo Zhang; Qing-Guang Zhang
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

6.  Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.

Authors:  Lao H Saal; Lisa Rydén; Daniel Förnvik; Kristina E Aaltonen; Yilun Chen; Anthony M George; Christian Brueffer; Robert Rigo; Niklas Loman
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

7.  Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer.

Authors:  Luc Y Dirix; Steffi Oeyen; Andy Buys; Vincent Liégois; Annemie Prové; Tom Van De Mooter; Steven Van Laere; Peter B Vermeulen
Journal:  Breast Cancer Res Treat       Date:  2022-02-08       Impact factor: 4.872

Review 8.  Role of circulating tumor cell spheroids in drug resistance.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Cancer Drug Resist       Date:  2019-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.